Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 13, 2023, the Board of Directors of Apexigen, Inc. (the "Company")
appointed Francis Sarena, current Chief Operating Officer of the Company, to the
role of President. Mr. Sarena will retain his role as Chief Operating Officer,
in addition to his new position as President of the Company, becoming the
Company's President and Chief Operating Officer. At this time, there have been
no changes to Mr. Sarena's compensation arrangements with the Company in
connection with his appointment as President. Xiaodong Yang, M.D., Ph.D., who
formerly served as President and Chief Executive Officer of the Company, will
continue as the Company's Chief Executive Officer.
Mr. Sarena, age 52, has served as the Company's Chief Operating Officer since
July 2022. He has also served as Chief Operating Officer of Apexigen America,
Inc., the Company's wholly owned subsidiary, since January 2022. From December
2010 to May 2021, Mr. Sarena was with Five Prime Therapeutics, Inc., a
biotechnology company, where he served in various executive roles, most recently
as Chief Strategy Officer and Secretary. From December 2008 to July 2010, he
served as Vice President, General Counsel and Secretary at Facet Biotech
Corporation, a biotechnology company. Mr. Sarena holds a B.S. in Finance from
San Francisco State University and a J.D. from University of California,
Berkeley.
There is no family relationship between Mr. Sarena and any director or executive
officer of the Company. In addition, Mr. Sarena is not a party to any
transaction, or series of transactions, required to be disclosed pursuant to
Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
APEXIGEN, INC. 
